CN Stock MarketDetailed Quotes

Shandong Xinhua Pharmaceutical (000756)

Watchlist
  • 14.08
  • -0.18-1.26%
Market Closed Apr 30 15:00 CST
9.81BMarket Cap37.45P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Shandong Xinhua Pharmaceutical (000756) Revenue Breakdown Overview

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Tablets, injections, capsules, etc.3.99B45.52%
Antipyretic analgesic and other raw materials2.65B30.22%
Pharmaceutical intermediates and others2.12B24.26%

By Industry

Currency:CNY
2025/FY
Stock NameRevenueRatio
Preparation3.99B45.52%
Chemical raw material2.65B30.22%
Pharmaceutical intermediates and others2.12B24.26%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
China6.79B77.50%
America745.57M8.52%
Europe712.82M8.14%
Other511.11M5.84%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +8.93%
Sample Name
Sample Code
 +6.50%
Sample Name
Sample Code
 +5.03%
4
CHINA OILFIELD
02883
+4.76%
5
SINOPEC CORP
00386
+2.67%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +46.25%
Sample Name
Sample Code
 +33.47%
Sample Name
Sample Code
 +26.48%
4
Loongson Technology Corporation
688047
+24.63%
5
Rockchip Electronics
603893
+19.54%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Iran has announced its latest negotiation proposal: all issues should be resolved within 30 days, with the focus on 'ending the war' rather Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -